2017 American Transplant Congress
A Novel, Dose-Adjusted Tacrolimus Trough Concentration (TTC) Model for Prediction and Variance Estimation.
Given that a high tacrolimus (tac) intrapatient variability (IPV) increases the risk for a poor kidney transplant (tx) outcome, some experts advocate routine IPV monitoring…2017 American Transplant Congress
Evolution of CCR4highCD4+ Subpopulations in Renal Graft Blood After Steroid Withdrawal: A Prospective, Randomized, Controlled Study in Parallel Groups. Preliminary Results.
Introduction:Steroids are a mainstay of immunosuppression after kidney transplant (KT). The infiltration into the graft of active T cells following KT depends on the expression…2017 American Transplant Congress
This is Why We Can't Have Nice Things- Real World Experience with Everolimus in Livers.
Purpose: To determine if discontinuation rates of everolimus (RAD) in clinical practice is higher than the 30% demonstrated in trials.Methods: This was a retrospective cohort…2017 American Transplant Congress
Baseline Immune Assessment to Individualize Immunosuppression in SPK Recipients with Type 1 Diabetes.
Introduction:Type 1 diabetes (T1D) is an immune-mediated disorder associated with multiple immunological anomalies. Immunologic abnormalities might help to explain why recipients of simultaneous pancreas kidney…2017 American Transplant Congress
Belatacept in Chronic Kidney Disease Stabilizes and Improves Renal Function in Pancreas Transplant Recipients: Intermediate Results.
Indiana University Health, Indianapolis
Background: We report our experience in converting Pancreas Transplant recipients from tacrolimus to Belatacept in order to avoid further worsening of kidney function.Results: Eight (7…2017 American Transplant Congress
Mycophenolate Dose Reductions Are Not Associated with De Novo Donor-Specific Antibodies.
University of Colorado, Aurora, CO
De novo donor-specific antibodies (dnDSA) are central to the development of antibody-mediated rejection, which is the most important cause of death-censored graft loss. It is…2017 American Transplant Congress
Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.
Department of Medicine, University of Maryland Medical Center, Baltimore, MD
The optimal approach for IS reduction in renal transplant recipients with BKN is not well defined. A number of clinical and in vitro studies suggest…2017 American Transplant Congress
Outcomes Following Reduction of Immunosuppression in Solid Organ Transplant Recipients with Cryptococcosis.
Background: Cryptococcosis (crypto) is the third most common fungal infection in solid organ transplant (SOT) recipients. Although reduction of immunosuppression (IS) may improve patient outcomes…2017 American Transplant Congress
Infectious Complications Following Hepatectomy for Pediatric Hepatoblastoma.
Pediatric Surgery, Baylor College of Medicine, Houston, TX
Purpose: To examine if patients with hepatoblastoma (HB) treated with both immunosuppression and chemotherapy have different rates of infection post-operatively than those treated with chemotherapy…2017 American Transplant Congress
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Indiana University Health, Indianapolis
Background: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. The…
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 138
- Next Page »